The pathophysiology of pituitary adenomas

Best Practice and Research: Clinical Endocrinology and Metabolism

Volumn 23, Issue 5, 2009, Pages 525-541

  Dworakowska, Dorota ^a,b   Grossman, Ashley B ^a  

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^b MEDICAL UNIVERSITY OF GDANSK   (Poland)

Author keywords

molecular alteration; pathophysiology; pituitary adenoma

Indexed keywords

AROMATIC HYDROCARBON RECEPTOR; BETA CATENIN; CORTICOTROPIN; CYCLIC AMP DEPENDENT PROTEIN KINASE REGULATORY SUBUNIT IALPHA; CYCLIN DEPENDENT KINASE INHIBITOR 1B; FIBROBLAST GROWTH FACTOR; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN KINASE B; SECURIN;

CELL CYCLE REGULATION; CELL TRANSPORT; GENE MUTATION; GENETIC ASSOCIATION; GENETIC DISORDER; HUMAN; HYPOPHYSIS ADENOMA; MICROARRAY ANALYSIS; NONHUMAN; ONCOGENE; PATHOPHYSIOLOGY; PROTEIN ANALYSIS; REVIEW; RISK ASSESSMENT; RISK FACTOR; SIGNAL TRANSDUCTION; TUMOR SUPPRESSOR GENE;

ADENOMA; GENES, CDC; GENES, TUMOR SUPPRESSOR; GENETIC PREDISPOSITION TO DISEASE; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; MODELS, BIOLOGICAL; ONCOGENES; PITUITARY NEOPLASMS; SIGNAL TRANSDUCTION; SYNDROME;

EID: 71749119235     PISSN: 1521690X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.beem.2009.05.004     Document Type: Review

References (131)

1. Scheithauer B.W., Gaffey T.A., Lloyd R.V., et al. Pathobiology of pituitary adenomas and carcinomas. Neurosurgery 59 (2006) 341-353 [discussion -53]
2. Ezzat S., Asa S.L., Couldwell W.T., et al. The prevalence of pituitary adenomas: a systematic review. Cancer 101 (2004) 613-619
3. Daly A.F., Burlacu M.C., Livadariu E., et al. The epidemiology and management of pituitary incidentalomas. Hormone Research 68 Suppl. 5 (2007) 195-198
4. Lindholm J., Juul S., Jorgensen J.O., et al. Incidence and late prognosis of Cushing's syndrome: a population-based study. The Journal of Clinical Endocrinology and Metabolism 86 (2001) 117-123
5. Levy A. Molecular and trophic mechanisms of tumorigenesis. Endocrinology and Metabolism Clinics of North America 37 (2008) 23-50 vii
6. Alexander J.M., Biller B.M., Bikkal H., et al. Clinically nonfunctioning pituitary tumors are monoclonal in origin. The Journal of Clinical Investigation 86 (1990) 336-340
7. Herman V., Fagin J., Gonsky R., et al. Clonal origin of pituitary adenomas. The Journal of Clinical Endocrinology and Metabolism 71 (1990) 1427-1433
8. Melmed S. Pituitary neoplasia. Endocrinology and Metabolism Clinics of North America 23 (1994) 81-92
9. Gueorguiev M., and Grossman A.B. Pituitary gland and beta-catenin signaling: from ontogeny to oncogenesis. Pituitary (2008)
10. Levy A., and Lightman S. Molecular defects in the pathogenesis of pituitary tumours. Frontiers in Neuroendocrinology 24 (2003) 94-127
11. Boikos S.A., and Stratakis C.A. Molecular genetics of the cAMP-dependent protein kinase pathway and of sporadic pituitary tumorigenesis. Human Molecular Genetics 16 Spec No 1 (2007) R80-R87
12. Beckers A., and Daly A.F. The clinical, pathological, and genetic features of familial isolated pituitary adenomas. European Journal of Endocrinology 157 (2007) 371-382
13. Karhu A., and Aaltonen L.A. Susceptibility to pituitary neoplasia related to MEN-1, CDKN1B and AIP mutations: an update. Human Molecular Genetics 16 Spec No 1 (2007) R73-R79
14. Horvath A., and Stratakis C.A. Clinical and molecular genetics of acromegaly: MEN1, Carney complex, McCune-Albright syndrome, familial acromegaly and genetic defects in sporadic tumors. Reviews in Endocrine & Metabolic Disorders 9 (2008) 1-11
15. Pellegata N.S., Quintanilla-Martinez L., Siggelkow H., et al. Germ-line mutations in p27Kip1 cause a multiple endocrine neoplasia syndrome in rats and humans. Proceedings of the National Academy of Sciences of the United States of America 103 (2006) 15558-15563
16. Vierimaa O., Georgitsi M., Lehtonen R., et al. Pituitary adenoma predisposition caused by germline mutations in the AIP gene. Science 312 (2006) 1228-1230
17. Igreja S., Chahal H.S., Akker S.A., et al. Assessment of p27 (cyclin-dependent kinase inhibitor 1B) and AIP (aryl hydrocarbon receptor-interacting protein) genes in MEN1 syndrome patients without any detectable MEN1 gene mutations. Clinical Endocrinology (2008)
18. Luccio-Camelo D.C., Une K.N., Ferreira R.E., et al. A meiotic recombination in a new isolated familial somatotropinoma kindred. European Journal of Endocrinology 150 (2004) 643-648
19. Daly A.F., Jaffrain-Rea M.L., Ciccarelli A., et al. Clinical characterization of familial isolated pituitary adenomas. The Journal of Clinical Endocrinology and Metabolism 91 (2006) 3316-3323
20. Spada A., Arosio M., Bochicchio D., et al. Clinical, biochemical, and morphological correlates in patients bearing growth hormone-secreting pituitary tumors with or without constitutively active adenylyl cyclase. The Journal of Clinical Endocrinology and Metabolism 71 (1990) 1421-1426
21. Lania A., Mantovani G., and Spada A. Genetics of pituitary tumors: focus on G-protein mutations. Experimental Biology and Medicine (Maywood, N.J.) 228 (2003) 1004-1017
22. Burgess J.R., Greenaway T.M., and Shepherd J.J. Expression of the MEN-1 gene in a large kindred with multiple endocrine neoplasia type 1. Journal of Internal Medicine 243 (1998) 465-470
23. Farrell W.E., Simpson D.J., Bicknell J., et al. Sequence analysis and transcript expression of the MEN1 gene in sporadic pituitary tumours. British Journal of Cancer 80 (1999) 44-50
24. Satta M.A., Korbonits M., Jacobs R.A., et al. Expression of menin gene mRNA in pituitary tumours. European Journal of Endocrinology 140 (1999) 358-361
25. Poncin J., Stevenaert A., and Beckers A. Somatic MEN1 gene mutation does not contribute significantly to sporadic pituitary tumorigenesis. European Journal of Endocrinology 140 (1999) 573-576
26. Dahia P.L., Aguiar R.C., Honegger J., et al. Mutation and expression analysis of the p27/kip1 gene in corticotrophin-secreting tumours. Oncogene 16 (1998) 69-76
27. Hai N., Aoki N., Shimatsu A., et al. Clinical features of multiple endocrine neoplasia type 1 (MEN1) phenocopy without germline MEN1 gene mutations: analysis of 20 Japanese sporadic cases with MEN1. Clinical Endocrinology 52 (2000) 509-518
28. Georgitsi M., Raitila A., Karhu A., et al. Germline CDKN1B/p27Kip1 mutation in multiple endocrine neoplasia. The Journal of Clinical Endocrinology and Metabolism 92 (2007) 3321-3325
29. Lloyd R.V., Jin L., Qian X., et al. Aberrant p27kip1 expression in endocrine and other tumors. The American Journal of Pathology 150 (1997) 401-407
30. Lidhar K., Korbonits M., Jordan S., et al. Low expression of the cell cycle inhibitor p27Kip1 in normal corticotroph cells, corticotroph tumors, and malignant pituitary tumors. The Journal of Clinical Endocrinology and Metabolism 84 (1999) 3823-3830
31. Milne T.A., Hughes C.M., Lloyd R., et al. Menin and MLL cooperatively regulate expression of cyclin-dependent kinase inhibitors. Proceedings of the National Academy of Sciences of the United States of America 102 (2005) 749-754
32. Drosten M., Hilken G., Bockmann M., et al. Role of MEN2A-derived RET in maintenance and proliferation of medullary thyroid carcinoma. Journal of the National Cancer Institute 96 (2004) 1231-1239
33. Kolluri S.K., Weiss C., Koff A., et al. p27(Kip1) induction and inhibition of proliferation by the intracellular Ah receptor in developing thymus and hepatoma cells. Genes & Development 13 (1999) 1742-1753
34. Kirschner L.S., Carney J.A., Pack S.D., et al. Mutations of the gene encoding the protein kinase A type I-alpha regulatory subunit in patients with the Carney complex. Nature Genetics 26 (2000) 89-92
35. Bossis I., Voutetakis A., Matyakhina L., et al. A pleiomorphic GH pituitary adenoma from a Carney complex patient displays universal allelic loss at the protein kinase A regulatory subunit 1A (PRKARIA) locus. Journal of Medical Genetics 41 (2004) 596-600
36. Sandrini F., Kirschner L.S., Bei T., et al. PRKAR1A, one of the Carney complex genes, and its locus (17q22-24) are rarely altered in pituitary tumours outside the Carney complex. Journal of Medical Genetics 39 (2002) e78
37. Kaltsas G.A., Kola B., Borboli N., et al. Sequence analysis of the PRKAR1A gene in sporadic somatotroph and other pituitary tumours. Clinical Endocrinology 57 (2002) 443-448
38. Georgitsi M., Raitila A., Karhu A., et al. Molecular diagnosis of pituitary adenoma predisposition caused by aryl hydrocarbon receptor-interacting protein gene mutations. Proceedings of the National Academy of Sciences of the United States of America 104 (2007) 4101-4105
39. Daly A.F., Vanbellinghen J.F., Khoo S.K., et al. Aryl hydrocarbon receptor-interacting protein gene mutations in familial isolated pituitary adenomas: analysis in 73 families. The Journal of Clinical Endocrinology and Metabolism 92 (2007) 1891-1896
40. Gadelha M.R., Une K.N., Rohde K., et al. Isolated familial somatotropinomas: establishment of linkage to chromosome 11q13.1-11q13.3 and evidence for a potential second locus at chromosome 2p16-12. The Journal of Clinical Endocrinology and Metabolism 85 (2000) 707-714
41. Leontiou C.A., Gueorguiev M., van der Spuy J., et al. The role of the aryl hydrocarbon receptor-interacting protein gene in familial and sporadic pituitary adenomas. The Journal of Clinical Endocrinology and Metabolism 93 (2008) 2390-2401
42. Asa S.L., and Ezzat S. The pathogenesis of pituitary tumours. Nature Reviews. Cancer 2 (2002) 836-849
43. Karga H.J., Alexander J.M., Hedley-Whyte E.T., et al. Ras mutations in human pituitary tumors. The Journal of Clinical Endocrinology and Metabolism 74 (1992) 914-919
44. Herman V., Drazin N.Z., Gonsky R., et al. Molecular screening of pituitary adenomas for gene mutations and rearrangements. The Journal of Clinical Endocrinology and Metabolism 77 (1993) 50-55
45. Boggild M.D., Jenkinson S., Pistorello M., et al. Molecular genetic studies of sporadic pituitary tumors. The Journal of Clinical Endocrinology and Metabolism 78 (1994) 387-392
46. Cryns V.L., Alexander J.M., Klibanski A., et al. The retinoblastoma gene in human pituitary tumors. The Journal of Clinical Endocrinology and Metabolism 77 (1993) 644-646
47. Pei L., Melmed S., Scheithauer B., et al. Frequent loss of heterozygosity at the retinoblastoma susceptibility gene (RB) locus in aggressive pituitary tumors: evidence for a chromosome 13 tumor suppressor gene other than RB. Cancer Research 55 (1995) 1613-1616
48. Tanizaki Y., Jin L., Scheithauer B.W., et al. P53 gene mutations in pituitary carcinomas. Endocrine Pathology 18 (2007) 217-222
49. Zhang X., Horwitz G.A., Heaney A.P., et al. Pituitary tumor transforming gene (PTTG) expression in pituitary adenomas. The Journal of Clinical Endocrinology and Metabolism 84 (1999) 761-767
50. Zhang X., Sun H., Danila D.C., et al. Loss of expression of GADD45 gamma, a growth inhibitory gene, in human pituitary adenomas: implications for tumorigenesis. The Journal of Clinical Endocrinology and Metabolism 87 (2002) 1262-1267
51. Zhang X., Zhou Y., Mehta K.R., et al. A pituitary-derived MEG3 isoform functions as a growth suppressor in tumor cells. The Journal of Clinical Endocrinology and Metabolism 88 (2003) 5119-5126
52. Bahar A., Simpson D.J., Cutty S.J., et al. Isolation and characterization of a novel pituitary tumor apoptosis gene. Molecular Endocrinology 18 (2004) 1827-1839
53. Pei L., and Melmed S. Isolation and characterization of a pituitary tumor-transforming gene (PTTG). Molecular Endocrinology 11 (1997) 433-441
54. Salehi F., Kovacs K., Scheithauer B.W., et al. Pituitary tumor-transforming gene in endocrine and other neoplasms: a review and update. Endocrine-related Cancer 15 (2008) 721-743
55. Bharadwaj R., and Yu H. The spindle checkpoint, aneuploidy, and cancer. Oncogene 23 (2004) 2016-2027
56. Zou H., McGarry T.J., Bernal T., et al. Identification of a vertebrate sister-chromatid separation inhibitor involved in transformation and tumorigenesis. Science 285 (1999) 418-422
57. Wang Z., and Melmed S. Pituitary tumor transforming gene (PTTG) transforming and transactivation activity. The Journal of Biological Chemistry 275 (2000) 7459-7461
58. Chamaon K., Kirches E., Kanakis D., et al. Regulation of the pituitary tumor transforming gene by insulin-like-growth factor-I and insulin differs between malignant and non-neoplastic astrocytes. Biochemical and Biophysical Research Communications 331 (2005) 86-92
59. Tong Y., Tan Y., Zhou C., et al. Pituitary tumor transforming gene interacts with Sp1 to modulate G1/S cell phase transition. Oncogene 26 (2007) 5596-5605
60. Chesnokova V., Zonis S., Rubinek T., et al. Senescence mediates pituitary hypoplasia and restrains pituitary tumor growth. Cancer Research 67 (2007) 10564-10572
61. Chesnokova V., Kovacs K., Castro A.V., et al. Pituitary hypoplasia in Pttg-/- mice is protective for Rb+/- pituitary tumorigenesis. Molecular Endocrinology 19 (2005) 2371-2379
62. Filippella M., Galland F., Kujas M., et al. Pituitary tumour transforming gene (PTTG) expression correlates with the proliferative activity and recurrence status of pituitary adenomas: a clinical and immunohistochemical study. Clinical Endocrinology 65 (2006) 536-543
63. McCabe C.J., Boelaert K., Tannahill L.A., et al. Vascular endothelial growth factor, its receptor KDR/Flk-1, and pituitary tumor transforming gene in pituitary tumors. The Journal of Clinical Endocrinology and Metabolism 87 (2002) 4238-4244
64. Minematsu T., Suzuki M., Sanno N., et al. PTTG overexpression is correlated with angiogenesis in human pituitary adenomas. Endocrine Pathology 17 (2006) 143-153
65. Saez C., Japon M.A., Ramos-Morales F., et al. hpttg is over-expressed in pituitary adenomas and other primary epithelial neoplasias. Oncogene 18 (1999) 5473-5476
66. Minematsu T., Egashira N., Kajiya H., et al. PTTG is a secretory protein in human pituitary adenomas and in mouse pituitary tumor cell lines. Endocrine Pathology 18 (2007) 8-15
67. Powers C.J., McLeskey S.W., and Wellstein A. Fibroblast growth factors, their receptors and signaling. Endocrine-related Cancer 7 (2000) 165-197
68. Givol D., and Yayon A. Complexity of FGF receptors: genetic basis for structural diversity and functional specificity. The FASEB Journal 6 (1992) 3362-3369
69. Ezzat S., Smyth H.S., Ramyar L., et al. Heterogenous in vivo and in vitro expression of basic fibroblast growth factor by human pituitary adenomas. The Journal of Clinical Endocrinology and Metabolism 80 (1995) 878-884
70. Ezzat S., Zheng L., Zhu X.F., et al. Targeted expression of a human pituitary tumor-derived isoform of FGF receptor-4 recapitulates pituitary tumorigenesis. The Journal of Clinical Investigation 109 (2002) 69-78
71. Qian Z.R., Sano T., Asa S.L., et al. Cytoplasmic expression of fibroblast growth factor receptor-4 in human pituitary adenomas: relation to tumor type, size, proliferation, and invasiveness. The Journal of Clinical Endocrinology and Metabolism 89 (2004) 1904-1911
72. Musat M., Vax V.V., Borboli N., et al. Cell cycle dysregulation in pituitary oncogenesis. Frontiers of Hormone Research 32 (2004) 34-62
73. Ogino A., Yoshino A., Katayama Y., et al. The p15(INK4b)/p16(INK4a)/RB1 pathway is frequently deregulated in human pituitary adenomas. Journal of Neuropathology and Experimental Neurology 64 (2005) 398-403
74. Yoshino A., Katayama Y., Ogino A., et al. Promoter hypermethylation profile of cell cycle regulator genes in pituitary adenomas. Journal of Neuro-oncology 83 (2007) 153-162
75. Bahar A., Bicknell J.E., Simpson D.J., et al. Loss of expression of the growth inhibitory gene GADD45gamma, in human pituitary adenomas, is associated with CpG island methylation. Oncogene 23 (2004) 936-944
76. Simpson D.J., Clayton R.N., and Farrell W.E. Preferential loss of Death Associated Protein kinase expression in invasive pituitary tumours is associated with either CpG island methylation or homozygous deletion. Oncogene 21 (2002) 1217-1224
77. Farrell W.E. A novel apoptosis gene identified in the pituitary gland. Neuroendocrinology 84 (2006) 217-221
78. Zhao J., Dahle D., Zhou Y., et al. Hypermethylation of the promoter region is associated with the loss of MEG3 gene expression in human pituitary tumors. The Journal of Clinical Endocrinology and Metabolism 90 (2005) 2179-2186
79. Pagotto U., Arzberger T., Theodoropoulou M., et al. The expression of the antiproliferative gene ZAC is lost or highly reduced in nonfunctioning pituitary adenomas. Cancer Research 60 (2000) 6794-6799
80. Korbonits M., Chahal H.S., Kaltsas G., et al. Expression of phosphorylated p27(Kip1) protein and Jun activation domain-binding protein 1 in human pituitary tumors. The Journal of Clinical Endocrinology and Metabolism 87 (2002) 2635-2643
81. Jordan S., Lidhar K., Korbonits M., et al. Cyclin D and cyclin E expression in normal and adenomatous pituitary. European Journal of Endocrinology 143 (2000) R1-R6
82. Ruebel K.H., Leontovich A.A., Jin L., et al. Patterns of gene expression in pituitary carcinomas and adenomas analyzed by high-density oligonucleotide arrays, reverse transcriptase-quantitative PCR, and protein expression. Endocrine 29 (2006) 435-444
83. Evans C.O., Young A.N., Brown M.R., et al. Novel patterns of gene expression in pituitary adenomas identified by complementary deoxyribonucleic acid microarrays and quantitative reverse transcription-polymerase chain reaction. The Journal of Clinical Endocrinology and Metabolism 86 (2001) 3097-3107
84. Evans C.O., Moreno C.S., Zhan X., et al. Molecular pathogenesis of human prolactinomas identified by gene expression profiling, RT-qPCR, and proteomic analyses. Pituitary 11 (2008) 231-245
85. Moreno C.S., Evans C.O., Zhan X., et al. Novel molecular signaling and classification of human clinically nonfunctional pituitary adenomas identified by gene expression profiling and proteomic analyses. Cancer Research 65 (2005) 10214-10222
86. Elston M.S., Gill A.J., Conaglen J.V., et al. Wnt pathway inhibitors are strongly down-regulated in pituitary tumors. Endocrinology 149 (2008) 1235-1242
87. Morris D.G., Musat M., Czirjak S., et al. Differential gene expression in pituitary adenomas by oligonucleotide array analysis. European Journal of Endocrinology 153 (2005) 143-151
88. Ribeiro-Oliveira A., Franchi G., Kola B., et al. Protein western array analysis in human pituitary tumours: insights and limitations. Endocrine-related Cancer (2008)
89. Zhan X., Evans C.O., Oyesiku N.M., et al. Proteomics and transcriptomics analyses of secretagogin down-regulation in human non-functional pituitary adenomas. Pituitary 6 (2003) 189-202
90. Beranova-Giorgianni S., Zhao Y., Desiderio D.M., et al. Phosphoproteomic analysis of the human pituitary. Pituitary 9 (2006) 109-120
91. Morris D.G., Kola B., Borboli N., et al. Identification of adrenocorticotropin receptor messenger ribonucleic acid in the human pituitary and its loss of expression in pituitary adenomas. The Journal of Clinical Endocrinology and Metabolism 88 (2003) 6080-6087
92. Dahia P.L., Honegger J., Reincke M., et al. Expression of glucocorticoid receptor gene isoforms in corticotropin-secreting tumors. The Journal of Clinical Endocrinology and Metabolism 82 (1997) 1088-1093
93. de Keyzer Y., Rene P., Beldjord C., et al. Overexpression of vasopressin (V3) and corticotrophin-releasing hormone receptor genes in corticotroph tumours. Clinical Endocrinology 49 (1998) 475-482
94. Dieterich K.D., Gundelfinger E.D., Ludecke D.K., et al. Mutation and expression analysis of corticotropin-releasing factor 1 receptor in adrenocorticotropin-secreting pituitary adenomas. The Journal of Clinical Endocrinology and Metabolism 83 (1998) 3327-3331
95. Dahia P.L., Ahmed-Shuaib A., Jacobs R.A., et al. Vasopressin receptor expression and mutation analysis in corticotropin-secreting tumors. The Journal of Clinical Endocrinology and Metabolism 81 (1996) 1768-1771
96. Korbonits M., Bujalska I., Shimojo M., et al. Expression of 11 beta-hydroxysteroid dehydrogenase isoenzymes in the human pituitary: induction of the type 2 enzyme in corticotropinomas and other pituitary tumors. The Journal of Clinical Endocrinology and Metabolism 86 (2001) 2728-2733
97. Rabbitt E.H., Ayuk J., Boelaert K., et al. Abnormal expression of 11 beta-hydroxysteroid dehydrogenase type 2 in human pituitary adenomas: a prereceptor determinant of pituitary cell proliferation. Oncogene 22 (2003) 1663-1667
98. Bilodeau S., Vallette-Kasic S., Gauthier Y., et al. Role of Brg1 and HDAC2 in GR trans-repression of the pituitary POMC gene and misexpression in Cushing disease. Genes & Development 20 (2006) 2871-2886
99. Drouin J., Bilodeau S., and Vallette S. Of old and new diseases: genetics of pituitary ACTH excess (Cushing) and deficiency. Clinical Genetics 72 (2007) 175-182
100. Lee E.J., Kotlar T.J., Ciric I., et al. Absence of constitutively activating mutations in the GHRH receptor in GH-producing pituitary tumors. The Journal of Clinical Endocrinology and Metabolism 86 (2001) 3989-3995
101. Salvatori R., Thakker R.V., Lopes M.B., et al. Absence of mutations in the growth hormone (GH)-releasing hormone receptor gene in GH-secreting pituitary adenomas. Clinical Endocrinology 54 (2001) 301-307
102. Kola B., Korbonits M., Diaz-Cano S., et al. Reduced expression of the growth hormone and type 1 insulin-like growth factor receptors in human somatotroph tumours and an analysis of possible mutations of the growth hormone receptor. Clinical Endocrinology 59 (2003) 328-338
103. Asa S.L., Digiovanni R., Jiang J., et al. A growth hormone receptor mutation impairs growth hormone autofeedback signaling in pituitary tumors. Cancer Research 67 (2007) 7505-7511
104. Greenman Y., Prager D., and Melmed S. The IGF-I receptor sub-membrane domain is intact in GH-secreting pituitary tumours. Clinical Endocrinology 42 (1995) 169-172
105. Petersenn S., Heyens M., Ludecke D.K., et al. Absence of somatostatin receptor type 2 A mutations and gip oncogene in pituitary somatotroph adenomas. Clinical Endocrinology 52 (2000) 35-42
106. Ballare E., Persani L., Lania A.G., et al. Mutation of somatostatin receptor type 5 in an acromegalic patient resistant to somatostatin analog treatment. The Journal of Clinical Endocrinology and Metabolism 86 (2001) 3809-3814
107. Giacomini D., Acuna M., Gerez J., et al. Pituitary action of cytokines: focus on BMP-4 and gp130 family. Neuroendocrinology 85 (2007) 94-100
108. Paez-Pereda M., Giacomini D., Refojo D., et al. Involvement of bone morphogenetic protein 4 (BMP-4) in pituitary prolactinoma pathogenesis through a Smad/estrogen receptor crosstalk. Proceedings of the National Academy of Sciences of the United States of America 100 (2003) 1034-1039
109. Korbonits M., Kojima M., Kangawa K., et al. Presence of ghrelin in normal and adenomatous human pituitary. Endocrine 14 (2001) 101-104
110. Nanzer A.M., Khalaf S., Mozid A.M., et al. Ghrelin exerts a proliferative effect on a rat pituitary somatotroph cell line via the mitogen-activated protein kinase pathway. European Journal of Endocrinology 151 (2004) 233-240
111. Adjei A.A., and Hidalgo M. Intracellular signal transduction pathway proteins as targets for cancer therapy. Journal of Clinical Oncology 23 (2005) 5386-5403
112. Rodriguez-Viciana P., Warne P.H., Khwaja A., et al. Role of phosphoinositide 3-OH kinase in cell transformation and control of the actin cytoskeleton by Ras. Cell 89 (1997) 457-467
113. Kauffmann-Zeh A., Rodriguez-Viciana P., Ulrich E., et al. Suppression of c-Myc-induced apoptosis by Ras signalling through PI(3)K and PKB. Nature 385 (1997) 544-548
114. Volarevic S., and Thomas G. Role of S6 phosphorylation and S6 kinase in cell growth. Progress in Nucleic Acid Research and Molecular Biology 65 (2001) 101-127
115. Inoki K., Li Y., Zhu T., et al. TSC2 is phosphorylated and inhibited by Akt and suppresses mTOR signalling. Nature Cell Biology 4 (2002) 648-657
116. Sonenberg N., and Gingras A.C. The mRNA 5′ cap-binding protein eIF4E and control of cell growth. Current Opinion in Cell Biology 10 (1998) 268-275
117. Rosenwald I.B., Kaspar R., Rousseau D., et al. Eukaryotic translation initiation factor 4E regulates expression of cyclin D1 at transcriptional and post-transcriptional levels. The Journal of Biological Chemistry 270 (1995) 21176-21180
118. Musat M., Korbonits M., Kola B., et al. Enhanced protein kinase B/Akt signalling in pituitary tumours. Endocrine-related Cancer 12 (2005) 423-433
119. Dworakowska D., and Grossman A. Are neuroendocrine tumours a feature of tuberous sclerosis?. Endocrine-related Cancer 16 (2009) 45-58
120. Haystead T.A., Dent P., Wu J., et al. Ordered phosphorylation of p42mapk by MAP kinase kinase. FEBS Letters 306 (1992) 17-22
121. Terada Y., Nakashima O., Inoshita S., et al. Mitogen-activated protein kinase cascade and transcription factors: the opposite role of MKK3/6-p38K and MKK1-MAPK. Nephrology, Dialysis, Transplantation 14 Suppl. 1 (1999) 45-47
122. Terada Y., Inoshita S., Nakashima O., et al. Regulation of cyclin D1 expression and cell cycle progression by mitogen-activated protein kinase cascade. Kidney International 56 (1999) 1258-1261
123. Guan K.L. The mitogen activated protein kinase signal transduction pathway: from the cell surface to the nucleus. Cellular Signalling 6 (1994) 581-589
124. Joneson T., and Bar-Sagi D. Ras effectors and their role in mitogenesis and oncogenesis. Journal of Molecular Medicine 75 (1997) 587-593
125. Ewing I., Pedder-Smith S., Franchi G., et al. A mutation and expression analysis of the oncogene BRAF in pituitary adenomas. Clinical Endocrinology 66 (2007) 348-352
126. Dworakowska D, Teng M, Grozinsky-Glasberg S, et al. Extracellular signal-regulated kinase (ERK 1/2) overactivation in pituitary adenomas. The Endocrine Society's 90th Annual Meeting 2008, San Francisco, USA; 2008: [P3-514].
127. Hibberts N.A., Simpson D.J., Bicknell J.E., et al. Analysis of cyclin D1 (CCND1) allelic imbalance and overexpression in sporadic human pituitary tumors. Clinical Cancer Research 5 (1999) 2133-2139
128. McCubrey J.A., Steelman L.S., Abrams S.L., et al. Roles of the RAF/MEK/ERK and PI3K/PTEN/AKT pathways in malignant transformation and drug resistance. Advances in Enzyme Regulation 46 (2006) 249-279
129. Vlotides G., Siegel E., Donangelo I., et al. Rat prolactinoma cell growth regulation by epidermal growth factor receptor ligands. Cancer Research 68 (2008) 6377-6386
130. Carbia-Nagashima A., Gerez J., Perez-Castro C., et al. RSUME, a small RWD-containing protein, enhances SUMO conjugation and stabilizes HIF-1alpha during hypoxia. Cell 131 (2007) 309-323
131. Simpson D.J., Hibberts N.A., McNicol A.M., et al. Loss of pRb expression in pituitary adenomas is associated with methylation of the RB1 CpG island. Cancer Research 60 (2000) 1211-1216